Elevated orexin levels in Alzheimer’s disease have been linked to accelerated cognitive decline, according to a prospective observational study involving sixty older adults with biomarker-confirmed mild to moderate Alzheimer’s disease. The study found that increased concentrations of cerebrospinal fluid orexin correlate with significant declines in global cognition and memory over a period of thirty-six months. Additionally, higher orexin levels are associated with worsening cerebrospinal fluid biomarkers indicative of neurodegeneration and neuroinflammation, including total tau, phosphorylated tau, and YKL-40. These results suggest that orexinergic hyperactivity may reflect a more aggressive disease trajectory in clinical settings.
Read More
The study involved participants undergoing baseline overnight polysomnography, followed by morning lumbar punctures and serial neuropsychological assessments. Notably, orexin concentrations did not correlate with conventional sleep metrics such as total sleep time, sleep latency, or sleep efficiency. However, the neuropeptide displayed specific inverse relationships with the microarchitecture of non-rapid eye movement sleep. Patients with lower sleep spindle density, shorter spindle duration, and reduced slow oscillation duration had the highest orexin concentrations. Additionally, baseline orexin levels were significantly higher in women than in men, indicating sex-specific neuroendocrine dynamics that should be considered in clinical evaluations.
Importantly, moderation analyses indicated that robust non-rapid eye movement oscillatory activity protects against the neurotoxic effects of orexin in Alzheimer’s disease. Increased sleep spindle density, spindle power, and prolonged slow oscillations significantly lessened the negative associations between elevated orexin levels and various cognitive assessment scores, including the Mini-Mental State Examination and the Alzheimer’s Disease Assessment Scale cognitive subscale. These synchronized sleep rhythms also helped to mitigate worsening scores in neuropsychiatric symptom inventories, operating independently of baseline amyloid and tau levels, thus preserving cortical stability.
For healthcare professionals treating dementia, these findings highlight the significance of electrophysiological sleep quality in providing neural resilience against neurodegenerative conditions. The study suggests that therapeutic strategies, including dual orexin receptor antagonists and noninvasive slow-wave enhancement, may be effective in reducing the excitotoxicity associated with orexin in Alzheimer’s disease. Nevertheless, as orexin signaling also plays a crucial role in maintaining physiological arousal, future therapeutic approaches must include careful monitoring of sleep architecture to prevent oversedation while optimizing cognitive outcomes for patients.
Reference: Paez A et al. Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience. Neurology. 2026;107(3):e218307.